The effects of donepezil in Alzheimer's disease - Results from a multinational trial

Dementia and Geriatric Cognitive Disorders

Volumn 10, Issue 3, 1999, Pages 237-244

  Burns, A ^a   Rossor, M ^b   Hecker, J ^c   Gauthier, S ^d   Petit, H ^e   Moller H J ^f   Rogers, S L ^g,h   Friedhoff, L T ⁱ  

^a WITHINGTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

^d MCGILL UNIVERSITY   (Canada)

^e UNIV LILLE   (France)

^f UNIVERSITY OF MUNICH   (Germany)

^g EISAI INC   (United States)

^h EISAI CO LTD   (Japan)

ⁱ NONE

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Efficacy safety

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; VERTIGO; VOMITING;

EID: 0032926540     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017126     Document Type: Article

References (31)

1. Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR, Danigues JF, Engedal K, Hagnell O, Heeren TJ: Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 1991;30:381-390.
2. Wenk GL: The nucleus basalis magnocellularis cholinergic system: One hundred years of progress. Neurobiol Learn Mem 1997;67:85-95.
3. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K: Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors; in Nagatsu T, Yoshida M, Fisher A (eds): Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. New York, Plenum Press, 1990, pp 409-413.
4. Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998;46(suppl 1):1-6.
5. Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998;46(suppl 1):7-12.
6. Tiseo PJ, Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998;46(suppl 1):13-18.
7. Rogers SL, Yamanishi Y, Yamatsu K: E2020: The pharmacology of a piperidine cholinesterase inhibitor; in Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston, Birkhäuser, 1991, pp 314-320.
8. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki Y, Morishita N: Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31:223-229.
9. Rogers SL, Friedhoff LT, and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303.
10. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Arch Int Med 1998; 158:1021-1031.
11. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
12. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
13. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(suppl 1):25-29.
14. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and ketoconazole: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(suppl 1):30-34.
15. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force in Alzheimer's disease. Neurology 1984;34:939-944.
17. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State'. A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975;12:189-198.
18. Hughes CD, Berg L, Danziger L, Coben LA, Martin RL: A new rating scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
19. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
20. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH, the Alzheimer's Disease Cooperative Study: Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2); S22-S32.
21. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G: Mild senile dementia of the Alzheimer type: 4 evaluations of intervention. Ann Neurol 1992;31:242-249.
22. Teunisse S, Derix M, van Crevel H: Assessing the severity of dementia, patient and caregiver. Arch Neurol 1991;48:274-277.
23. Blau TH: Quality of life, social indicators and criteria of change. Prof Psychol 1977;8:464-473.
24. Leber P: US Food and Drug Administration, Center for Drug Evaluation and Research, Division of Neuropharmacological Drug Products. Form and Contents of NDA Reviews: Strategies for the Efficacy Analysis. November 5, 1985.
25. 2 tests. Biometrics 1954;10:417-451.
26. Bross IDJ: How to use RIDIT analysis. Biometrics 1958;14:18-38.
27. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Epidemiology and Biostatistics: COSTART: Coding symbols for thesaurus of adverse reaction terms, ed 4. Pub PB93-209138, 1993.
28. Rogers SL, Friedhoff LT: Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease. Eur Neuropsychopharmacol 1997;7(S2):S251.
29. US Package Insert: Aricept® (donepezil hydrochloride tablets), September 1998.
30. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
31. Doraiswamy PM: Current cholinergic therapy for symptoms of Alzheimer's Disease. Primary Psychiatry 1996;3(11):56-68.